Neose Technologies Newswire

Neose Technologies Newswire

Comprehensive Real-Time News Feed for Neose Technologies.

Results 1 - 20 of 117 in Neose Technologies

  1. -$0.30 EPS Expected for Intec Pharma (NTEC) This QuarterRead the original story w/Photo

    Thursday Oct 11 | AmericanBankingNews.com

    Wall Street brokerages expect that Intec Pharma will post earnings of per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Intec Pharma's earnings.

    Comment?

  2. Oppenheimer Analysts Give Intec Pharma (NTEC) a $15.00 Price TargetRead the original story w/Photo

    Monday Oct 1 | AmericanBankingNews.com

    The brokerage currently has a "buy" rating on the biotechnology company's stock. Oppenheimer's price target indicates a potential upside of 165.49% from the stock's current price.

    Comment?

  3. Intec Pharma (NTEC) Receives Consensus Rating of "Buy" from AnalystsRead the original story w/Photo

    Sunday Sep 30 | AmericanBankingNews.com

    Intec Pharma has earned a consensus recommendation of "Buy" from the seven brokerages that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company.

    Comment?

  4. Brokerages Expect Intec Pharma (NTEC) to Post -$0.29 Earnings Per ShareRead the original story w/Photo

    Saturday Sep 29 | Daily Political

    Wall Street brokerages expect Intec Pharma to announce earnings per share of for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Intec Pharma's earnings, with the highest EPS estimate coming in at and the lowest estimate coming in at .

    Comment?

  5. Prosight Management LP Invests $4.95 Million in Intec Pharma (NTEC) StockRead the original story w/Photo

    Sep 10, 2018 | AmericanBankingNews.com

    Prosight Management LP acquired a new position in Intec Pharma during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,125,153 shares of the biotechnology company's stock, valued at approximately $4,951,000.

    Comment?

  6. Intec Pharma (NTEC) Receives Consensus Rating of "Buy" from BrokeragesRead the original story w/Photo

    Sep 6, 2018 | AmericanBankingNews.com

    Shares of Intec Pharma have been assigned an average recommendation of "Buy" from the eight brokerages that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company.

    Comment?

  7. DAFNA Capital Management LLC Purchases New Holdings in Intec PharmaRead the original story w/Photo

    Sep 3, 2018 | AmericanBankingNews.com

    DAFNA Capital Management LLC purchased a new position in shares of Intec Pharma during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 568,600 shares of the biotechnology company's stock, valued at approximately $2,502,000.

    Comment?

  8. Intec Pharma (NTEC) Earning Somewhat Favorable News Coverage, Study ShowsRead the original story w/Photo

    Sep 1, 2018 | The Breeze

    Media stories about Intec Pharma have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources.

    Comment?

  9. Intec Pharma (NTEC) Hits New 52-Week Low at $3.70Read the original story w/Photo

    Aug 25, 2018 | IntersportsWire

    Shares of Intec Pharma hit a new 52-week low during trading on Thursday . The stock traded as low as $3.70 and last traded at $3.80, with a volume of 1210 shares trading hands.

    Comment?

  10. -$0.30 EPS Expected for Intec Pharma (NTEC) This QuarterRead the original story w/Photo

    Aug 24, 2018 | Daily Political

    Brokerages forecast that Intec Pharma will report earnings per share of for the current quarter, Zacks reports. Zero analysts have issued estimates for Intec Pharma's earnings, with the lowest EPS estimate coming in at and the highest estimate coming in at .

    Comment?

  11. Intec Pharma (NTEC) Given a $15.00 Price Target by Oppenheimer AnalystsRead the original story w/Photo

    Aug 15, 2018 | AmericanBankingNews.com

    The brokerage presently has a "buy" rating on the biotechnology company's stock. Oppenheimer's price target suggests a potential upside of 261.45% from the company's previous close.

    Comment?

  12. Intec Pharma (NTEC) Receives Coverage Optimism Rating of 0.12Read the original story w/Photo

    Aug 12, 2018 | The Breeze

    Headlines about Intec Pharma have been trending somewhat positive recently, Accern reports. The research group rates the sentiment of press coverage by analyzing more than twenty million blog and news sources.

    Comment?

  13. Intec Pharma Ltd (NTEC) Given Consensus Rating of "Buy" by BrokeragesRead the original story w/Photo

    Aug 12, 2018 | AmericanBankingNews.com

    Shares of Intec Pharma Ltd have been given a consensus rating of "Buy" by the eight analysts that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have given a buy recommendation to the company.

    Comment?

  14. Intec Pharma Ltd (NTEC) Receives Average Recommendation of "Buy" from BrokeragesRead the original story w/Photo

    Aug 12, 2018 | IntersportsWire

    Intec Pharma Ltd has received an average recommendation of "Buy" from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company.

    Comment?

  15. Analysts Anticipate Intec Pharma Ltd (NTEC) to Announce -$0.32 EPSRead the original story w/Photo

    Aug 11, 2018 | IntersportsWire

    Analysts expect that Intec Pharma Ltd will post earnings of per share for the current fiscal quarter, according to Zacks . Zero analysts have provided estimates for Intec Pharma's earnings, with the lowest EPS estimate coming in at and the highest estimate coming in at .

    Comment?

  16. Brokerages Expect Intec Pharma Ltd (NTEC) to Post -$0.32 Earnings Per ShareRead the original story w/Photo

    Aug 4, 2018 | AmericanBankingNews.com

    Equities research analysts expect Intec Pharma Ltd to report earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Intec Pharma's earnings, with estimates ranging from to .

    Comment?

  17. Zacks Investment Research Downgrades Intec Pharma (NTEC) to SellRead the original story w/Photo

    Jul 29, 2018 | Daily Political

    According to Zacks, "Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology.

    Comment?

  18. Intec Pharma Ltd (NTEC) Given Consensus Rating of "Buy" by AnalystsRead the original story w/Photo

    Jul 18, 2018 | AmericanBankingNews.com

    Intec Pharma Ltd has received a consensus recommendation of "Buy" from the eight research firms that are covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company.

    Comment?

  19. Intec Pharma (NTEC) Earns Media Sentiment Rating of 0.07Read the original story w/Photo

    Jul 7, 2018 | IntersportsWire

    News coverage about Intec Pharma has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources.

    Comment?

  20. Intec Pharma (NTEC) Receives Buy Rating from Roth CapitalRead the original story w/Photo

    Jun 27, 2018 | IntersportsWire

    Roth Capital currently has a $10.00 price objective on the biotechnology company's stock. Other analysts have also recently issued reports about the company.

    Comment?